Immunomodulatory activities of fluoroquinolones

Infection, Supplement

Volumn 33, Issue 2, 2005, Pages 55-70

  Dalhoff, A ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYTOKINE; DEXAMETHASONE; DNA TOPOISOMERASE (ATP HYDROLYSING); FOLINIC ACID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GREPAFLOXACIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; MOXIFLOXACIN; NALIDIXIC ACID; NORFLOXACIN; OFLOXACIN; PENTOXIFYLLINE; PHOSPHODIESTERASE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RUFLOXACIN; SPARFLOXACIN; TRANSCRIPTION FACTOR AP 1; TROVAFLOXACIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; YT 1; AMIFLOXACIN; CLINDAMYCIN; CYCLIC AMP; DIFLOXACIN; ENOXACIN; FLEROXACIN; I KAPPA B KINASE GAMMA; LEVOFLOXACIN; METRONIDAZOLE; PEFLOXACIN; PIPEMIDIC ACID; QUINOLONE; TEMAFLOXACIN; TRANSCRIPTION FACTOR; UNINDEXED DRUG;

ABDOMINAL INFECTION; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTEROIDES FRAGILIS; CANCER CELL; CELLULAR IMMUNITY; CHLAMYDOPHILA PNEUMONIAE; CYTOKINE PRODUCTION; DNA REPAIR; DRUG CYTOTOXICITY; DRUG STRUCTURE; EX VIVO STUDY; HEMATOPOIESIS; HUMAN; HUMORAL IMMUNITY; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; CELL LINE; CELL STIMULATION; CORRELATION ANALYSIS; CYTOKINE RELEASE; DATA ANALYSIS; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG INDUCED CANCER; EUKARYOTE; GENETIC SUSCEPTIBILITY; GENOTOXICITY; INFECTION; INFLAMMATION; SYNTHESIS; UPREGULATION;

ANIMALS; ANTI-BACTERIAL AGENTS; CYTOKINES; FLUOROQUINOLONES; HEMATOPOIESIS; HUMANS; IMMUNITY; SIGNAL TRANSDUCTION;

EID: 31444454103     PISSN: 01732129     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-005-8209-8     Document Type: Review

References (148)

1. Riesbeck K, Andersson J, Gullberg M, Forsgren A: Fluorinated 4-quinolones induce hyperproduction of interleukin 2. Proc Natl Acad Sci 1989; 86: 2809-2813.
2. Roche Y, Fay M, Gougerot-Pocidalo MA: Effect of quinolones on interleukin-1 production in vitro by human monocytes. Immunopharmacology 1987; 13: 99-109.
3. Zehavi-Wilner T, Shalit I: Enhancement of interleukin-2 production in human lymphocytes by two new quinolone derivatives. Lymph Res 1989; 8: 35-46.
4. Forsgren A, Bredberg A, Riesbeck K: New quinolones: in vitro effects as potential source of clinical toxicity. Rev Infect Dis 1989; 11 (Suppl. 5): S1382-S1389.
5. Dalhoff A, Zeiler HJ (eds): Handbook of experimental pharmacology, vol. 127. Springer Verlag, Berlin, Heidelberg 1998, pp 233-257.
6. Nau R, Eiffert H: Modulation of release of proinflammatory bacterial compounds by antibacterial: potential impact on course of inflammation and outcome in sepsis and meningitis. Clin Microbiol Rev 2002; 15: 95-110.
7. Edlund C, Nord CE: Effect of quinolones on intestinal ecology. Drugs 1999; 58 (Suppl. 2): 65-70.
8. Schubert S, Ullmann U: Effect of antibiotics on chemotaxis, phagocytosis of polymorphonuclear leukocytes and lymphocyte transformation with special reference to modern beta-lactams and fluoroquinolones. In: Ullmann U, Dalhoff A (eds): Significance of cytokines in the treatment of infectious diseases. Fischer, Stuttgart 1993, pp 111-136.
9. Tulkens PM: Intracellular distribution and activity of antibiotics. Eur J Clin Microbiol Infect Dis 1991; 10: 100-106.
10. Labro MT: Interference of antibacterial agents with phagocyte functions: immunomodulation or "immuno-fairy tales"? Clin Microbiol Rev 2000; 13: 615-650.
11. Riesbeck K: Immunomodulating activity of quinolones: review. J Chemother 2002; 14: 3-12.
12. Hooper DC: Fluoroquinolone resistance among gram-positive cocci. Lancet Infect Dis 2002; 2: 530-538.
13. Hooper DC, Wolfson JS: Mechanisms of quinolone action and bacterial killing. In: Hooper DC, Wolfson JS (eds): Quinolone antibacterial agents, 2nd edn. American Society for Microbiology, Washington, DC 1993, pp 53-75.
14. Schmitz FJ, Higgins PG, Mayer S, Fluit AC, Dalhoff A: Activity of 7 quinolones against gram-positive cocci: mechanisms of drug action and bacterial resistance. Eur J Clin Microbiol Infect Dis 2002; 21: 647-659.
15. Gootz TD, Osheroff N: Quinolones and eukaryotic topoisomerasis. In: Hooper DC, Wolfson JS (eds): Quinolone antimicrobial agents, 2nd edn. American Society for Microbiology, Washington DC 1993; 139-160.
16. Hussy P, Maas G, Tümmler B, Grosse F, Schomburg U: Effect of 4-quinolones and novobiocin on calf-thymus DNA-polymerase primase complex, topoisomerase I and II, and growth of mammalian lymphoblasts. Antimicrob Agents Chemother 1986; 29: 1073-1078.
17. Mandell GL, Coleman E: Uptake, transport and delivery of antimicrobial agents by human polymorphonuclear neutrophils. Antimicrob Agents Chemother 2001; 45: 1794-1798.
18. Nix DE: Intrapulmonary concentrations of antimicrobial agents. Infect Dis Clin North Am 1998; 12: 631-646.
19. Forsgren A, Schlossman SF, Tedder TF: 4-quinolone drugs affect cell cycle progression and function of human lymphocytes in vitro. Antimicrob Agents Chemother 1987; 31: 768-773.
20. Forsgren A, Bredberg A, Pardee AB, Schlossman SF, Tedder TF: Effects of ciprofloxacin on eukaryotic pyrimidine nucleotide biosynthesis and cell growth. Antimicrob Agents Chemother 1987; 31: 774-779.
21. De Simone C, Baldinelli L, Ferrazzi M, De Santis S, Pugnaloni L, Sorice F: Influence of ofloxacin, norfloxacin, nalidixic acid, pyromidic acid and pipemidic acid on human γ-interferon production and blastogenesis. J Antimicrob Chemother 1986; 17: 811-814.
22. Gollapudi S, Perumal V, Thadepalli H: Effect of rufloxacin on in-vitro proliferation and differentiation of human mononuclear cells. J Antimicrob Chemother 1992; 29: 669-676.
23. Zakeri SM, Meyer H, Meinhardt G, Reinisch W, Schrattbauer K, Knoefler M, Block LH: Effects of trovafloxacin on the II-1 dependent activation of E-selectin in human endothelial cells in vitro. Immunopharmacology 2000; 48: 27-34.
24. Gootz TD, Osheroff N: Quinolones and eukaryotic topoisomerases. In: Hooper DC, Rubinstein E (eds): Quinolone antimicrobial agents, 3rd edn. ASM-Press, Washington DC 2003, pp 69-89.
25. Gollapudi SVS, Prabhala H, Thadepalli H: Effect of ciprofloxacin on mitogen stimulated lymphocyte proliferation. Antimicrob Agents Chemother 1986; 29: 337-338.
26. Hooper DC, Wolfson JS: Adverse effects. In: Hooper DC, Wolfson JS (eds): Quinolone antimicrobial agents, 2nd edn. American Society for Microbiology, Washington DC 1993; pp 489-512.
27. von Keutz E, Christ W: Toxicology and safety pharmacology of quinolones. In: Kuhlmann J, Dalhoff A, Zeiler HJ (eds): Quinolone antibacterials. Handbook of experimental pharmacology vol. 127. Springer-Verlag, Berlin, Heidelberg 1998, pp 297-337.
28. Schlüter G: Ciprofloxacin: review of potential toxicologic effects. Am J Med 1987; 82 (Suppl. 4A): 91-96.
29. Bailly S, Fay M, Gougerot-Pocidalo JJ: Effects of quinolones on tumor necrosis factor production by human monocytes. Int J Immunopharmacol 1990; 12: 31-36.
30. Stunkel KGE, Hewlett G, Zeiler HJ: Ciprofloxacin enhances T cell function by modulating interleukin activities. Clin Exp Immunol 1991; 86: 525-531.
31. Shalit I, Kletter Y, Weiss K, Gruss T, Fabian I: Enhanced hematopoiesis in sublethally irradiated mice treated with various quinolones. Eur J Haematol 1997; 58: 92-98.
32. Riesbeck K, Forsgren A: Selective enhancement of synthesis of interleukin-2 in lymphocytes in the presence of ciprofloxacin. Europ J Clin Microbiol Infect Dis 1990; 9: 409.
33. Riesbeck K, Forsgren A: Increased interleukin-2 transcription in murine lymphocytes by ciprofloxacin. Immunopharmacology 1994; 27: 155-164.
34. Azuma Y, Shinohara M, Murakawa N, Ohura K: Possible interaction between new quinolones and immune functions in macrophages. Gen Pharmacol 1999; 32: 609-614.
35. Azuma Y, Wang PL, Shinohara M, Suese MY, Ohura K: Comparative studies of modulatory effect to the function of rat peritoneal neutrophils treated with new quinolones. Immunol Lett 1999; 69: 321-327.
36. Araujo FG, Slifer TL, Remington JS: Effect of moxifloxacin on secretion of cytokines by human monocytes stimulated with lipopolysaccharide. Clin Microbiol Infect 2002; 8: 26-30.
37. Khan AS, Slifer TR, Remington JS: Effect of trovafloxacin on production of cytokines by human monocytes. Antimicrob Agents Chemother 1998; 42: 1713-1717.
38. Riesbeck K, Gullberg M, Forsgren A: Evidence that the antibiotic Ciprofloxacin counteracts cyclosporine-dependent suppression of cytokine production. Transplantation 1994; 57: 267-272.
39. Riesbeck K, Forsgren A, Henriksson A, Bredberg A: Ciprofloxacin induces an immunomodulatory stress response in human T lymphocytes. Antimicrob Agents Chemother 1998; 42: 1923-1930.
40. Riesbeck K, Sigvardsson T, Leanderson T, Forsgren A: Superinduction of cytokine gene transcription by Ciprofloxacin. J Immunol 1994; 153: 343-352.
41. Roche Y, Gougerot-Pocidalo MA, Fay M, Etienne D, Forest N, Pocidalo JJ: Comparative effects of quinolones on human mononuclear leucocyte functions. J Antimicrob Chemother 1987; 19: 781-790.
42. Bailly S, Fay M, Ferrua B, Gougerot-Pocidalo MA: Ciprofloxacin treatment in vivo increases the ex vivo capacity of lipopolysaccharide-stimulated human monocytes to produce II-1, II-6 and tumor-necrosis factor alpha. Clin Exp Immunol 1991; 85: 331-334.
43. Roche Y, Fay M, Gougerot-Pocidalo MA: Interleukin-1 production by antibiotic treated human monocytes. J Antimicrob Chemother 1988; 21: 597-607.
44. Bailly S, Pocidalo JJ, Fay M, Gougerot-Pocidalo MA: In vitro and in vivo effects of quinolones on monocyte cytokine production. In: Ullmann U, Dalhoff A (eds): Significance of cytokine in the treatment of infectious diseases. Gustav Fischer Verlag, Stuttgart, New York 1993, pp 137-149.
45. Bailly S, Mahe Y, Ferru B, Fay M, Tursz T, Wakasugi H, Gougerot-Pocidalo MA: Quinolone-induced differential modification of II-1α and II-1β production by LPS-stimulated human monocytes. Cell Immunol 1990; 128: 277-288.
46. Shalit I: Immunological aspects of new quinolones. Eur J Clin Microbiol Infect Dis 1991; 10: 262-266.
47. Yoshimura T, Kurita C, Usami E, Nakao T, Watanabe S, Kobayashi J, Yamazaki F, Nagai H: Immunomodulatory action of levofloxacin on cytokine production by human peripheral blood mononuclear cells. Chemotherapy 1996; 42: 459-464.
48. Kletter Y, Riklis I, Shalit I, Fabian I: Enhanced repopulation of murine hematopoietic organs in sublethally irradiated mice after treatment with ciprofloxacin. Blood 1991; 78: 1685-1691.
49. Galley HF, Nelson SJ, Dubbels AM, Webster NR: Effect of ciprofloxacin on the accumulation of interleukin-6, interleukin-8 and nitrite from a human endothelial cell model of sepsis. Crit Care Med 1997; 25: 1392-1395.
50. Galley HF, Dhillon JK, Paterson RL, Webster NR: Effect of ciprofloxacin on the activation of the transcription factors nuclear factor kappaB, activator protein-I and nuclear factor-interleukin-6, and interleukin-6 and interleukin-8 mRNA expression in a human endothelial cell line. Clin Sci 2000; 99: 405-410.
51. Khan AA, Slifer TR, Araujo FG, Suzuki Y, Remington JS: Protection against lipopolysaccharide-induced death by fluoroquinolones. Antimicrob Agents Chemother 2000; 44: 3169-3173.
52. Purswani MU, Eckert SJ, Arora HK, Noel GJ: Effect of ciprofloxacin on lethal and sublethal challenge with endotoxin and on early cytokine response in a murine in vivo model. J Antimicrob Chemother 2000; 50: 51-58.
53. Ouo Y, Ohmoto Y, Ouo K, Sakata Y, Murata K: Effect of grepafloxacin on cytokine production in vitro. J Antimicrob Chemother 2000; 46: 91-94
54. Choi JH, Song MJ, Kim SH, Choi SM, Lee DG, Yoo JH, Shin WS: Effect of moxifloxacin on production of proinfammatory cytokines from human peripheral blood mononuclear cells. Antimicrob Agents Chemother 2003; 47: 3704-3707.
55. Rabehi L, Irinopoulou T, Cholley B, Haeffner-Cavaillon N, Carreno MP: Gram-positive and Gram-negative bacteria do not trigger monocytic cytokine production through similar intracellular pathways. Infect Immun 2001; 69: 4590-4599.
56. Nitsche D, Schulze C, Oesser S, Dalhoff A, Sack M: Impact of different classes of antimicrobial agents on plasma endotoxin activity. Arch Surg 1996; 131: 192-199.
57. Lindner B, Wiese A, Brandenburg K, Seydel U, Dalhoff A: Lack of interaction of fluoroquinolones with lipopolysaccharides. Antimicrob Agents Chemother 2002; 46: 1568-1570.
58. Hashimoto S, Matsumoto K, Gon Y, Maruoka S, Hayashi S, Asai Y, Machino T, Horie T: Grepafloxacin inhibits tumor necrosis factor-α-induced interleukin-8 expression in human airway epithelial cells. Pharmacology Letters 2000; 66: 77-82.
59. Gollapudi S, Chuoh SK, Harvey T, Thadepalli HD, Tadepalli H: In vivo effects of rufloxacin and ciprofloxacin on T-cell subsets and tumor necrosis factor production in mice infected with Bacteroides fragilis. Antimicrob Agents Chemother 1993; 37: 1711-1712.
60. Tadepalli H, Gollapudi SV, Chuoh SK: Therapeutic evaluation of difloxacin (A-56618) and A 5620 for experimentally induced Bacteroides fragilis associated with intra-abdominal abscess. Antimicrob Agents Chemother 1986; 30: 574-576.
61. Thadepalli H, Hajji M, Perumal VK, Chuoh SK, Gollapudi S: Evaluation of temafloxacin in a rat model of intra-abdominal abscess. J Antimicrob Chemother 1992; 29: 687-692.
62. Thadepalli H, Reddy U, Chuoh SK, Thadepalli F, Malilay C, Polzer RJ, Hanna N, Esfandiari A, Brown P, Gollapudi S: In vivo efficacy of trovafloxacin (CP-99,217), a new quinolone, in experimental intra-abdominal abscesses caused by Bacteroides fragilis and Escherichia coli. Antimicrob Agents Chemother 1997; 41: 583-586.
63. Thadepalli H, Chuah SK, Reddy U, Hanna N, Clark R, Polzer RJ, Gollapudi S: Efficacy of trovafloxacin for treatment of experimental Bacteroides infection in young and senescent mice. Antimicrob Agents Chemother 1997; 41: 1933-1936.
64. King A, May J, French G, Phillips I: Comparative in vitro activity of gemifloxacin. J Antimicrob Chemother 2000; 45 (Suppl. 1): 1-12.
65. Nwariak FE, McIntyre KL, Sikes PJ, Mileski WJ: The effect of antimicrobial agents on the induction of tumor necrosis factor by alveolar macrophages in vitro in response to endotoxin. J Antimicrob Chemother 1997; 39: 265-267.
66. Purswani M, Eckert SJ, Arora HK, Johann-Liang R, Noel GJ: The effect of three broad-spectrum antimicrobials on mononuclear cell responses to encapsulated bacteria: evidence for down-regulation of cytokine mRNA transcription by trovafloxacin. J Antimicrob Chemother 2000; 46: 921-929.
67. Wandl U, Dalhoff A, Andes CU: Effect of antiinfective agents on human haematopoietic cell growth. In: Ullmann U, Dalhoff A (eds): Significance of cytokines in the treatment of infectious diseases. Gustav Fischer Verlag, Stuttgart, New York 1993, pp 159-169.
68. Pessina A, Neri MG, Muschiato A, Mineo E, Cocuzza G: Effect of fluoroquinolones on the in vitro proliferation of myeloid precursor cells. J Antimicrob Chemother 1989; 24: 203-208.
69. Pallavicini F, Antinori A, Fedrico G, Fantoni M, Nervo P: Influence of two quinolones, ofloxacin and pefloxacin, on human myelopoiesis in vitro. Antimicrob Agents Chemother 1989; 33: 122-123.
70. Somekh E, Douer D, Shaked N, Rubinstein E: In vitro effects of ciprofloxacin and pefloxacin on growth of normal human hematopoietic progenitor cells and on leukemic cell lines. J Pharmacol Exp Ther 1989; 248: 415-418.
71. Halin T, Barak Y, Liebovich E, Malach L, Dagan O, Rubinstein E: Ciprofloxacin inhibits human hematopoietic cell growth; synergism with tumor necrosis factor and interferon. Exp Hematol 1991; 19: 157.
72. Yamashita Y, Ashizawa T, Morimoto M, Hosomi J, Makano H: Antitumor quinolones with mammalian topoisomerase II mediated DNA cleavage activity. Cancer Res 1992; 52: 2818-2822.
73. Shalit I, Kletter Y, Halperin D, Waldmann D, Vassermann E, Nagler A, Fabian I: Immunomodulatory effects of moxifloxacin in comparison to ciprofloxacin and G-CSF in a murine model of cyclophosphamide-induced leukopenia. Eur J Haematol 2001; 66: 287-296.
74. Dranoff G, Crawford A, Sadelain M, Ream B, Rashid A, Bronson RT, Dickersin GR, Buchurski CJ, Mark EL, Whittsett JA, Milligan RC: Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis. Science 1994; 264: 713-716.
75. Lechner AJ, Lamprech KEE, Potthoff LH, Tredway TL, Matuschak GM: Recombinant GM-CSF reduces lung injury and mortality during neutropenic Candida sepsis. Am J Physiol 1994; 266: L561-568.
76. Stanley E, Lieschke GJ, Grail D, Metcalf D, Hodgson G, Gall JA, Maher DW, Cebon J, Simcas V, Dunn AR: Granulocyte/macrophage colony-stimulating factor deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc Natl Acad Sci USA 1994; 91: 5592-5596.
77. Shalit I, Horev-Azaria L, Fabian I, Blau H, Kariv N, Shechtman I, Alteraz H, Kletter Y: Immunomodulatory and protective effects of moxifloxacin against Candida albicans-induced bronchopneumonia in mice injected with cyclophosphamide. Antimicrob Agents Chemother 2002; 46: 2442-2449.
78. Cuffini AM, Tullio V, Alloeo A, Paizis G, DeLeo C, Carlone NA: Effect of rufloxacin upon non-specific immune defenses: in vitro, ex-vivo and in-vivo results. J Antimicrob Chemother 1994; 34: 545-553.
79. Zigoren L, Shoenfeld Y: Anti-phosholipid syndrome: from patient's bedside to experimental animal models and back to the patient's bedside. Hematol Cell Ther 1998; 40: 175-182.
80. Shoenfeld Y, Sherer Y, Fishman P: Interleukin-3 and pregnancy loss in antiphospholid syndrome. Scand J Rheumatol 1998; 27 (Suppl. 107): 19-22.
81. Savion S, Blank M, Shepshelovich J, Fishman P, Shoenfeld Y, Toder V: Ciprofloxacin affects pregnancy loss in CBA/J x DBA/2J mice possibly via elevation of interleukin-3 and granulocyte macrophage-colony stimulating factor production. Am J Reprod Immunol 2000; 44: 293-298.
82. Blank M, George J, Fishman P, Levy Y, Toder V, Savion S, Barak V, Koike T, Shoenfeld Y: Ciprofloxacin immunomodulation of experimental antiphospholipid syndrome associated with elevation of interleukin-3 and granulocyte macrophage stimulating factor expression. Arthritis Rheum 1998; 41: 224-232.
83. Stein RB, Hanauer SB: Medical therapy for inflammatory bowel disease. Gastroenterol Clin North Am 1999; 28: 297-231.
84. Griffiths AM: Crohn's disease in children and adolescents: what are the treatment options? Drugs Today 1999; 35 (Suppl. A): 5-16.
85. Rath HC, Schultz M, Freitag R, Dieleman LA, Li FL, Linde HJ, Scholmerich, J, Sartor B: Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice. Infect Immun 2001; 69: 2277-2285.
86. Lewis AJ, Keft AF: A review on the strategies for the development and application of new anti-arthritis agents. Immunopharmacol Immunotoxicol 1995; 17: 607-663.
87. Breban M, Fournier C, Gougerot-Pocidalo MA, Muffat-Joly M, Pocidalo JJ: Protective effects of ciprofloxacin against type II collagen induced arthritis in rats. J Rheumatol 1992; 19: 216-222.
88. Broide E, Douer D, Shaked N, Yellin A, Lieberman Y, Rosen N, Segev S, Rubinstein E: The effect of short-term therapy with ciprofloxacin, ceftriaxone and placebo on peripheral WBC and marrow-derived granulocytes-macrophage- progenitor cells (CFU-GM). Eur J Haematol 1992; 48: 276-277.
89. Eidelman G, Shapira Y, Lishner M, Shalit I, Kletter Y, Fabian I: Effect of ciprofloxacin on hematologic parameters in breast cancer patients receiving chemotherapy. Eur J Haematol 1995; 55: 202-204.
90. Imrie KR, Prince HM, Couture F, Brandwein JM, Keating A: Effect of antimicrobial prophylaxis on hematopoietic recovery following autologous bone marrow transplantation: ciprofloxacin versus co-trimoxazole. Bone Marrow Transplant 1995; 15: 267-270.
91. Lew MA, Kehoe K, Ritz J: Ciprofloxacin versus trimethoprim/ sulfamethoxazole for prophylaxis of bacterial infections in bone marrow transplant recipients: a randomised, controlled trial. J Clin Oncol 1995; 13: 239-250.
92. Freifeld A, Marchigiani D, Walsh T: A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 1999; 341: 305-311.
93. Yasumoto R, Kawano M, Tsujino T, Iwai Y, Hayashi S, Nishisaka N, Horii A, Kishimoto T: Seminal plasma cytokines in non-bacterial prostatitis: changes following sparfloxacin treatment. Acta Ruol Jpn 1995; 41: 771-774.
94. Togawa A, Kobayashi M, Saito T, Goto H, Kuki K, Yamanaka N: Effect of levofloxacin on rautes release from epithelial cells of nasal polyp. Int J Antimicrob Agents 2001; 17 (Suppl. 1): S84.
95. Yamanaka N, Togawa A, Kobayashi M, Kuki K: Immunomodulatory functions of levofloxacin. Int J Antimicrob Agents 2001; 17 (Suppl. 1): S53.
96. Kobayashi M, Saito T, Togawa A, Gotoh H, Kuki K, Yamanaka N: Influence of levofloxacin on cytokine production in human tonsillar lymphocytes. Practica Otologica 2000; 93: 887-892.
97. Krull M, Klucken AC, Wuppermann FN, Fuhrmann O, Magerl C, Seybold J, Hippenstiel S, Hegemann JH, Jantos CA, Suttorp N: Signal transduction pathways activated in endothelial cells following infection with Chlamydia pneumoniae. J Immunol 1999; 162: 4834-4841.
98. Dechend R, Maass M, Gieffers J, Scheidereit C, Dietz R, Leutz A, Gulba DC: Chlamydia pneumoniae infection induces NF-xB mediated upregulation of tissue factor and PAI-1 expression in vascular smooth muscle and endothelial cells - a potential link to accelerated arteriosclerotic disease. Circulation 1999; 100: 1369-1373.
99. Ross JS, Stagliano NE, Donovan MJ, Breitbart RE, Ginsburg GS: Atherosclerosis and cancer: common molecular pathways of disease development and progression. Ann NY Acad Sci 2001; 947: 271-292.
100. Maass M: Antiinflammatory modification of the signal transduction by moxifloxacin in a model of chronic Chlamydia pneumoniae infection. Personal Communication.
101. Buchmeier NA, Schreiber RD: Requirements of endogenous interferon-gamma production for resolution of Listeria monocytogenes infection. Proc Natl Acad Sci USA 1985; 82: 7404-7408.
102. Scorneaux B, Ouadrhiri Y, Anzalone G, Tulkens PM: Effect of recombinant human gamma interferon on intracellular activities of antibiotics against Listeria monocytogenes in the human macrophage cell line THP-1. Antimicrob Agents Chemother 1996; 40: 1225-1230.
103. Carryn S, Van Bambeke F, Mingeot-Leclerq MP, Tulkens PM: Comparative intracellular (THP-1 macrophage) and extracellular activities of beta-lactams, azithromycin, gentamicin, and fluoroquinolones against Listeria monocytogenes of clinically relevant concentrations. Antimicrob Agents Chemother 2002; 46: 2095-2103.
104. König B, König W: Moxifloxacin inhibits staphylococcal superantigen induced apoptosis in T-lymphocytes. 12th Congr Eur Soc Clin Microbiol Inf Dis, ECCMID, Milan, 2002: Abstr. P793.
105. Novitzky N, Mohamed R, Finlayson J, du Toit C: Increased apoptosis of bone marrow cells and preserved proliferative capacity of selected progenitors predict for clinical response to anti-inflammatory therapy in myclodysplastic syndromes. Exp Hematol 2000; 28: 941-949.
106. Denis M, Ghardirian E: Mycobacterium avium infection in HIV infected subjects increase monokine secretion and are associated with enhanced viral load and diminished immune responses to viral antigens. Clin Exp Immunol 1994; 97: 76-78.
107. Haverkos HW: Factors associated with the pathogenesis of AIDS. J Infect Dis 1987; 156: 250-257.
108. Birx DL, Redfield R, Tencer K, Fowler A, Burke DS, Tosato G: Induction of interleukin-6 during human immunodeficiency virus infection. Blood 1990; 11: 2303-2310.
109. Breen E, Rezai AR, Nakajima K, Beall G, Mitsuyasu R, Hirano T, Kishimoto I, Martinez-Maza U: Infection with HIC is associated with elevated II-6 levels and production. J Immunol 1990; 144: 480-484.
110. Kobayashi S, Hamamoto Y, Kobayashi N, Yamamoto N: Serum levels of TNF-a in HIV infected individuals. AIDS 1990; 4: 169-170.
111. Lepe-Zuniga JL, Mansel WA, Hersh EM: Idiopathic production of interleukin-1 in acquired immunodeficiency syndrome. J Clin Microbiol 1987; 25: 1695-1699.
112. Maury CPJ, Lahdevirta JL: Correlation of serum cytokine levels with hematological abnormalities in human immunodeficiency virus infections. J Intern Med 1990; 227: 253-257.
113. Sperber SJ, Schlupner CJ: Salmonellosis during infection with human immunodeficiency virus. Rev Infect Dis 1987; 9: 925-934.
114. Bottone EJ, Worser GP, Ducanson FP: Non-typhoidal Salmonella bacterimia as an early infection in acquired immunodeficiency syndrome. Diagn Microbiol Infect Dis 1984; 2: 247-250.
115. Poli G, Fauci AS: Cytokine modulation of HIV expression. Semin Immunol 1992; 5: 165-173.
116. Poli G, Kinter A, Justement JS, Kehrl JH, Bressler P, Stanley S, Fauci AS: Tumor necrosis factor alpha functions in an autocrine manner in the induction of human immunodeficiency virus infection. Proc Natl Acad Sci 1990; 87: 782-786.
117. Andreana A, Gollapudi S, Gupta S: Salmonella typhimurium activates human immunodeficiency virus type 1 in chronically infected promonocytic cells by inducing tumor necrosis factor a production. Biochem Biophys Res Commun 1994; 201: 16-23.
118. Mizel SB, Kucera LS, Richardson HS, Ciacci F, Iyer NP: Regulation of macrophage activation and human immunodeficiency virus production by invasive Salmonella strains. Infect Immun 1995; 63: 1820-1826.
119. Ciacci-Woolwine F, Kucera LS, Richardson HS, Iyer NP, Mizel SB: Salmonellae activate tumor necrosis factor alpha production in a human promonocytic cell line via released polypeptide. Infect Immun 1997; 65: 4624-4633.
120. Gollapudi S, Gupta S, Thadepalli H: Salmonella typhimurium-induced reactivation of latent HIV-1 in promonocytic U1 cells is inhibited by trovafloxacin. Int J Mol Med 2000; 5: 615-618.
121. Gollapudi S, Kim CH, Roshanravan B, Gupta S: Ciprofloxacin inhibits activation of latent human immunodeficiency virus type 1 in chronically infected promonocytic U1 cells. AIDS Res Hum Retroviruses 1998; 14: 499-504.
122. Loya S, Rudi M, Kasman Y, Loya Y, Hizi A: 3,5,8,trihydroxy-4-quinolone, a novel natural inhibitor of the reverse transcriptase of human immunodeficiency virus type 1 and type 2. Arch Biochem Biophys 1994; 309: 315-322.
123. Wang K, Bastow KF, Cosentino LM, Lee KH: Antitumor agents. 166. Synthesis and biological evaluation of 7,8 substituted 2 phenylthiochromen-4-one. J Med Chem 1996; 39: 1975-1980.
124. Witvrou W, Daelmans MD, Pannecouque C, Neyts J, Andrei G, Snoek R, Vandamme AM, Balzarini J, Desmyter J, Baba M, de Clerk E: Broad spectrum antiviral activity and mechanism of antiviral action of the fluoroquinolone derivative K-12. Antiviral Chem Chemother 1998; 9: 403-411.
125. Bayer HealthCare AG, data on file.
126. Dalhoff A, Shalit I: Immunomodulatory effects of quinolones. Lancet Infect Dis 2003; 3: 359-371.
127. Blaine TA, Pollice PF, Rosier RN, Reynolds PR, Puzas JE, O'Keefe RJ: Modulation of the production of cytokines in titanium-stimulated human peripheral blood monocytes by pharmacological agents. The role of cAMP-mediated signaling mechanisms. J Bone Joint Surg Am 1997; 79-A: 1519-1528.
128. Wang JP, Raung SL, Huang LJ, Kuo SC: Involvement of cyclic AMP generation in the inhibition of respiratory burst by 2-phenyl-4-quinolone (YT-1) in rat neutrophils. Biochem Pharmacol 1998; 56: 1505-1514.
129. Greenfield EM, Horowitz MC, Lavish SA: Stimulation by parathyroid hormone of interleukin-6 and leukemia inhibitory factor expression in osteoblasts is an immediate-early gene response induced by cAMP signal transduction. J Biol Chem 1996; 271: 10984-10989.
130. Han J, Brown T, Beutler B: Endotoxin-responsive sequences control cachectin/tumor necrosis factor biosynthesis at the translational level. J Exp Med 1990; 172: 391-394.
131. Ghosh S, Karin M: Missing pieces in the NF-kappaB puzzle. Cell 2002; 109: S81-S96.
132. Riesbeck K, Forsgren A, Henriksson A, Bredberg A: Ciprofloxacin induces an immunomodulatory stress response in human T lymphocytes. Antimicrob Agents Chemother 1998; 42: 1923-1930.
133. Blau H, Fabian I, Kletter Y, Shalit I: Protective immunomodulation by moxifloxacin against Candida albicans lung infection in cyclophosphamide treated mice: suppression of TNF-α, IL-8 and NFκB activation. Am J Resp Crit Care Med 2002; 165-A782.
134. Niwa M, Kanamori Y, Hotta K, Matsuno H, Kozawa O, Fujimoto S, Uematsu T: Priming by grepafloxacin on respiratory burst of human neutrophils: its possible mechanism. J Antimicrob Chemother 2002; 50: 469-478.
135. Petit JC, Daguet GL, Richard G, Burghofer B: Influence of ciprifloxacin and piperacillin on interleukin-1 production by murine macrophages. J Antimicrob Chemother 1987; 20: 615-617.
136. Simon DM, Koenig G, Trenholme GM: Differences in release of tumor necrosis factor from THP-1 cells stimulated by filtrates of antibiotic-killed Escherichia coli. J Infect Dis 1991; 164: 800-802.
137. Frieling JTM, Mulder JA, Hendricks T, Curfs JHAJ, van der Linden CJ, Sauerwein RW: Differential induction of pro- and anti-inflammatory cytokines in whole blood by bacteria: effects of antibiotic treatment. Antimicrob Agents Chemother 1997; 41: 1439-1443.
138. Galley HF, Nelson SJ, Dubbels AM, Webster NR: Effect of ciprofloxacin on the accumulation of interleukin-6, interleukin-8, and nitrite from a human endothelial cell model of sepsis. Crit Care Med 1997; 25: 1392-1395.
139. Riesbeck K, Anderssson J, Gullberg M, Forsgren A: Fluorinated 4-quinolones induce hyperproduction of interleukin 2. Proc Natl Acad Sci USA 1989; 86: 2809-2813.
140. Riesbeck K, Forsgren A: CP-115,953 stimulates cytokine production by lymphocytes. Antimicrob Agents Chemother 1995; 39: 476-483.
141. Riesbeck K, Forsghren A, Henriksson A, Bedberg A: Ciprofloxacin induces an immunomodulatory stress response in human T lymphocytes. Antimicrob Agents Chemother 1998; 42: 1923-1930.
142. Roche Y, Gougerot-Pocidalo MA, Fay M, Etienne D, Forest N, Pocidalo J: Comparative effects of quinolones on human leucocyte functions. J Antimicrob Chemother 1987; 19: 781-790.
143. Baily S, Mahe Y, Ferrua B, Fay M, Tursz T, Wakasugi H, Gougerot-Pocidalo MA: Quinolone-induced differential modification of II-1α and II-1β production by LPS stimulated human monocytes. Cell Immunol 1990; 128: 277-288.
144. Roche Y, Fay M, Gogerot-Pocidalo MA: Effects of quinolones on interleukin 1 production in vitro by human monocytes. Immunopharmacology 1987; 13: 99-109.
145. DeSimone C, Baldinelli L, Ferrazzi M, deSantis S, Pugnaloni L, Sorice F: Influence of ofloxacin, norfloxacin, nalidixic acid, pyromidic acid and pipemidic acid on human gamma-interferon production and blastogenesis. J Antimicrob Chemother 1986; 17: 811-814.
146. Matera G, Berlinghieri MC, Foti F, Barreca GS, Foca A: Effect of RO 23-9424, cefotaxime and fleroxacin on functions of human polymorphonuclear cells and cytokine production by human monocytes. J Antimicrob Chemother 1996; 38: 799-807.
147. Williams AC, Galley HF, Webster NR: The effect of moxifloxacin on release of interleukin-8 from human neutrophils. Br J Anaesth 2001; 87: 671-672.
148. Thadepalli H, Chuah SK, Gollapudi S: Therapeutic efficacy of moxifloxacin, a new quinolone, in the treatment of experimental intra-abdominal abscesses induced by Bacteroides fragilis in mice. Chemotherapy 2004; 50: 76-80.